Therapeutic trial in experimental tegumentary leishmaniasis caused by Leishmania (Leishmania) amazonensis. A comparative study between mefloquine and aminosidine.
One hundred and eighty-two male inbred C57/BL/6 mice were infected with 3 x 10(6) Leishmania (Leishmania) amazonensis promastigotes of the MHOM/BR/PH8 strain by means of a subcutaneous injection in the right ear. The animals were separated in three groups: 1) oral mefloquine hydrochloride treatment (16 mg/kg/day/10 days), 2) intramuscular aminosidine (Paromomycin) treatment (20 mg/kg/20 days) and 3) control. Twenty-six mice of each treated group were sacrificed, one at the end of treatment (nine weeks after inoculation), and one six weeks later (fifteen weeks after inoculation). Control Group animals were sacrificed at weeks six, nine and fifteen after inoculation. There was no significant difference between Group 1 (mefloquine) and Group 3 (control) subjects. Group 2 animals (aminosidine) presented the smallest differences of all, both at the end of the treatment and six weeks later. The histopato-logical parameters have shown the following findings: a) there was no significant difference between the mefloquine treated group and the control group; the group treated with aminosidine showed fewer of vacuolated macrophages than the control group, at week 9 (end of treatment). b) both at the end of treatment and six weeks later, evaluation of tissue necrosis and tissue fibrosis revealed no differences between the treated groups. It was found that six weeks after the end of treatment, mice in the control group presented significantly more severe degrees of fibrosis than mice in the other groups. It can be concluded that mefloquine showed limited therapeutic effect in this experimental model, whereas aminosidine had a significant effect. Nevertheless, neither of them resulted in cure of the lesions.
Pathology Department of Medicine School of the University of Brasília, DF, Brazil.
L O
LO
Galvão
S
S
Moreira Júnior
P
P
Medeiros Júnior
G J
GJ
Lemos
N F
NF
Cunha
R M
RM
Antonino
B S
BS
Santos Filho
A V
AV
Magalhães
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D007891:Leishmania; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D015767:Mefloquine / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D010303:Paromomycin / Q000627:therapeutic use*
D000981:Antiprotozoal Agents; D010303:Paromomycin; D015767:Mefloquine